Kristina Burow and Paul Berns, Neumora
ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer's and a lot more
ARCH Venture is doubling — and tripling and quadrupling — down on the belief that the 2020s will be neuroscience’s decade.
The VC firm, known for periodically …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
